2001•Anti-Cancer DrugsRequires access
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study
Florence Duffaud, M EL van der Burg, M Namer, I. Vergote, PH Willemse, W ten Bokkel Huinink, Jp. Guastalla, M. Nooij, Pierre Kerbrat, Martine Piccart, Salvatore Tumolo, G. Favalli, Nine van der Vange, A J Lacave, J. Wils, T. A. W. Splinter, N. Einhorn, K. J. Roozendaal, Roberta Rosso, J. B. Vermorken
Open publisher page 24 citations
Abstract
Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees). Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression. No objective responses were observed. Eleven out of 68 evaluable patients (16%) had stable disease. The median progression-free survival was 5 months in patients with disease stabilization and 2 months for all evaluable patients. The median survival for patients with disease stabilization was 17 months, whereas for all patients it was 4 months. The treatment was well tolerated; the only reported adverse events were incidental hot flushes. This study showed that the LHRH agonist Triptorelin has only modest efficacy in patients pretreated with platinum-containing chemotherapy.